PDCD4 and neoplasm: Our principal findings demonstrate that a 100-gene signature based on PDCD4 co-expression patterns robustly predicts patient survival with a hazard ratio of 2.17 while maintaining independent prognostic value after adjusting for established clinical variables including tumor stage and grade.